Discovery at MedDay
Our metabolomics platform, SPECMET, has the ability to identify specific metabolic signatures in major central nervous system disorders, providing numerous opportunities for further pipeline development. By focusing on compounds that already have known activity in neurometabolic pathways, we believe we can quickly demonstrate clinical proof of concept. Read more
Our pipeline currently comprises one lead candidate, MD1003, which has been developed into and through clinical trials, including two phase III studies in Progressive Multiple Sclerosis.